Connect with us

Biotech

R&D investment in the Spanish biotech sector increased by 13% in 2018

The biotech sector in Spain is committed to investments in R&D, as the latest report by Asebio showed. More than 70% of the total investments in R&D were made by biotech companies. Of the rest of the sectors, investment in R&D by all the companies increased by just over 6%, although the variability between the different branches of activity has been very high, ranging from more than 50% growth.

Published

on

This picture show a clock with a couple of coins.

Investment in R&D by biotechnology companies is growing at an increasingly high rate. In fact, there was an increase of 13% in 2018, according to the Annual Report on Biotechnology 2019 presented in June. The Spanish Association of Biocompanies (Asebio) thus highlighted the growth in R&D investment in the sector.

If you want to find more details about the biotech sector in Spain, and how committed are Spanish biotech companies to investments in R&D, download for free the Born2Invest mobile app. Be the first to find the most important business news in the world with our companion app.

The biotech sector among the sectors that invest more in R&D

The results of the Annual Biotechnology Report placed the biotech sector as one of the sectors that invests the most in R&D in Spain. The Spanish Association of Biocompanies (AseBio) presented its latest report, which highlighted that more than 70% of biotechnology investment in R&D corresponds to biotech companies. “This figure represents the sector’s commitment to science and innovation, which now, with the health crisis as a backdrop, is becoming more important than ever,” said Ion Arocena, CEO of AseBio.

This growth has been systematic since 2014, with an increasingly high rate, reaching a 13% increase during 2018. As for the “strictly” biotechnology companies, these registered a strong expansion, above 21%, according to the report. On the other hand, the secondary companies reduced their contribution significantly and those that use biotechnology as a production tool, showed a somewhat more moderate increase, around 8%.

For the first time, biotech is in the first place as the sector that invests most in R&D

Another point highlighted in the document is that, for the first time, biotech companies are in the first place as the sector that invests most in R&D, ahead of services and the education sector. And just ahead of the pharmaceutical sector. Furthermore, in relation to their production, they are the ones that invest the most, with 5.5% in relation to their production.

SEE ALSO  The Collection of Hermann and Margrit Rupf

In this aspect, they are only surpassed by organizations in the service sector of R&D and education. Furthermore, in 2018, biotech companies have overtaken the pharmaceutical sector, which traditionally occupied the first position after services and education.

The biotech sector is among the ten sectors with the highest growth, reaching three times the national average rate

With respect to the sectors that are growing most in R&D investment, biotech is in the top ten. Thus, the biotech sector is among the ten sectors with the highest growth, tripling the national average rate. Of the rest of the sectors, investment in R&D by all the companies increased by just over 6%, although the variability between the different branches of activity has been very high, ranging from more than 50% growth. For example, in sectors such as oil or wood, to fall above 10% in energy and water.

The Asebio report highlighted the high variability in companies that have biotechnology as a secondary activity. According to the report, that can be explained by the fact that some of the companies have changed their classification during 2018. So they have come to consider biotechnology as a tool in their processes.

__

(Featured image by nattanan23 via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in iSanidad, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Helene Lindbergh is a published author with books about entrepreneurship and investing for dummies. An advocate for financial literacy, she is also a sought-after keynote speaker for female empowerment. Her special focus is on small, independent businesses who eventually achieve financial independence. Helene is currently working on two projects—a bio compilation of women braving the world of banking, finance, crypto, tech, and AI, as well as a paper on gendered contributions in the rapidly growing healthcare market, specifically medicinal cannabis.